PRECIGEN, INC.
Precigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.
Friday’s jobs data showed 23,000 fewer jobs in July and May and June payrolls were revised down by 103,000, easing near-term Fed rate pressure. The 10-year Treasury yield fell to 4.64%. The S&P 500 rose 0.6% to a record as Q2 earnings showed near 50% profit growth. The article also lists options trades in NVO, SPCX, PGEN, OSCR, YOU, PLTR, CF, OUST, CMPS, and ATI.
PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec
Over the past 7 days, alphai's AI scored 2 news stories mentioning PGEN (PRECIGEN, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent PGEN coverage spans insider activity, earnings and financial news.
In the last 30 days, PGEN insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.1M). The most active reporter was Shah Rutul R, Chief Operating Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Q2 profitability and launch traction are offset by explicit margin normalization guidance and rising R&D as the pipeline advances.
PGEN is included due to explicit options trade details, not because of new fundamentals.
Q2 profitability tied to PAPZIMEOS commercial sales plus FDA seven-year exclusivity and a permanent J-code are near-term positive demand and reimbursement signals.
This is an insider selling disclosure, not a fundamental update. It may modestly affect near-term sentiment, but it does not change company fundamentals by itself.
Insider selling is unlikely to signal deteriorating fundamentals because the article frames it as pre-scheduled 10b5-1 activity, but it still adds near-term supply/overhang optics.
alphai scores every news story that mentions PGEN with an AI model for sentiment and relevance, and aggregates insider trades from PRECIGEN, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Precigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.
6 min readFriday’s jobs data showed 23,000 fewer jobs in July and May and June payrolls were revised down by 103,000, easing near-term Fed rate pressure. The 10-year Treasury yield fell to 4.64%. The S&P 500 rose 0.6% to a record as Q2 earnings showed near 50% profit growth. The article also lists options trades in NVO, SPCX, PGEN, OSCR, YOU, PLTR, CF, OUST, CMPS, and ATI.
7 min readPRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 dp251262_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflec
6 min readThomasian Harry Jr. (Chief Financial Officer) sold 100,000 shares of PRECIGEN, INC. (PGEN) at $6.06 ($0.61M total) on 2026-07-31 under a Rule 10b5-1 trading plan.
2 min readPrecigen (NASDAQ:PGEN) CFO Harry Thomasian Jr. sold 200,000 shares in open-market transactions from June 29 to July 1, 2026, for about $1.1 million, according to an SEC Form 4. The sale reduced his direct holdings to 354,535 shares. Precigen reported Q1 revenue of $23.3 million and received FDA orphan drug status for Papzimeos.
7 min readThomasian Harry Jr. (Chief Financial Officer) sold 200,000 shares of PRECIGEN, INC. (PGEN) at an average of $5.57 ($5.53–$5.78, $1.11M total) across 2 trades over 2026-06-29 to 2026-07-01 under a Rule 10b5-1 trading plan.
2 min readSabzevari Helen (President and CEO) sold 346,836 shares of PRECIGEN, INC. (PGEN) at $5.89 ($2.04M total) on 2026-06-29 under a Rule 10b5-1 trading plan.
1 min readPRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001356090 0001356090 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
3 min readPrecigen Inc. (PGEN) rose 11.62% to close at $5.38 on Monday for a second straight session. The gain followed the company’s late-month FDA approval granting six-year orphan drug exclusivity for Papzimeos to treat recurrent respiratory papillomatosis in the U.S., extending protection until Aug. 14, 2032, according to Precigen.
3 min readPrecigen CFO Harry Thomasian Jr. sold 41,884 shares on May 28, 2026, for about $182,614, according to an SEC Form 4. The shares were priced at $4.36, leaving him with 554,535 shares (~$2.50M) directly owned. Precigen reported TTM revenue of about $31.6M and a net loss of about $204.4M.
6 min read
